Insight Molecular Diagnostics, Inc. is a molecular diagnostics company, which engages in the development and commercialization of diagnostic tests for the detection of cancer, including molecular diagnostic services to pharmaceutical customers. Its products include DetermaRx and DetermaIO. The firm also offers pharmaceutical services like multi-analyte test development and clinical trial services. The company was founded in September 2009 and is headquartered in Nashville, TN.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
49
Frequently Asked Questions
What is Market Cap of Insight Molecular Diagnostics Inc.?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Insight Molecular Diagnostics Inc. market cap is $105.32M.
What is the 52-week high for Insight Molecular Diagnostics Inc.?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Insight Molecular Diagnostics Inc. 52 week high is $4.75 as of October 10, 2025.
What is the 52-week low for Insight Molecular Diagnostics Inc.?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Insight Molecular Diagnostics Inc. 52 week low is $1.92 as of October 10, 2025.
What is Insight Molecular Diagnostics Inc. stock price today?
Insight Molecular Diagnostics Inc. stock price today is $3.80.
What was Insight Molecular Diagnostics Inc. stock price yesterday?
Insight Molecular Diagnostics Inc. stock price yesterday was $3.68.
What is the PE ratio of Insight Molecular Diagnostics Inc.?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Insight Molecular Diagnostics Inc.’s P/E ratio is -1.06.
What is the Price-to-Book ratio of Insight Molecular Diagnostics Inc.?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Insight Molecular Diagnostics Inc. P/B ratio is 95.9083.
What is the 50-day moving average of Insight Molecular Diagnostics Inc.?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Insight Molecular Diagnostics Inc. 50-day moving average is $2.86.
How many employess does Insight Molecular Diagnostics Inc. has?
Insight Molecular Diagnostics Inc. has 49 employees.
